Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of UBT251 injection in overweight or obese adults with chronic kidney disease
CTR20252751Phase 2Active
- Sponsor
- The United Laboratories International Holdings
- Start
- Sep 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of UBT251 in chronic kidney disease (CKD), albuminuria, obesity, Overweight, sponsored by The United Laboratories International Holdings. Started Sep 2025; status: active.
02
Drugs
UBT251
03
Conditions
chronic kidney disease (CKD)albuminuriaobesityOverweight
Beyond the preview
Go deeper on CTR20252751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252751.